Antonella Isgro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2700716/publications.pdf

Version: 2024-02-01

35	1,332	331259	344852
papers	citations	21 h-index	36 g-index

36	36	36	1827
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Busulfanâ€“fludarabine- or treosulfanâ€“fludarabine-based myeloablative conditioning for children with thalassemia major. Annals of Hematology, 2022, 101, 655-665.	0.8	13
2	Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRÎ±Î²+/CD19+-depleted grafts. Blood Advances, 2018, 2, 263-270.	2.5	76
3	Histological features of bone marrow in paediatric patients during the asymptomatic phase of early-stage Black African sickle cell anaemia. Pathology, 2017, 49, 297-303.	0.3	1
4	Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies. Biology of Blood and Marrow Transplantation, 2017, 23, 1531-1540.	2.0	54
5	Optimal Outcomes in Young Class 3 Patients With Thalassemia Undergoing HLA-Identical Sibling Bone Marrow Transplantation. Transplantation, 2016, 100, 925-932.	0.5	44
6	Structural and Functional Insights on an Uncharacterized Aγ-Globin-Gene Polymorphism Present in Four β0-Thalassemia Families with High Fetal Hemoglobin Levels. Molecular Diagnosis and Therapy, 2016, 20, 161-173.	1.6	17
7	New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation. Pediatric Blood and Cancer, 2015, 62, 680-686.	0.8	17
8	Haematopoietic stem cell transplantation in Nigerian sickle cell anaemia children patients. Nigerian Medical Journal, 2015, 56, 175.	0.6	7
9	REDUCTION OF INTRAMEDULLARY APOPTOSIS AFTER STEM CELL TRANSPLANTATION IN BLACK AFRICAN VARIANT OF PEDIATRIC SICKLE CELL ANEMIA.. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014054.	0.5	2
10	Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. Bone Marrow Transplantation, 2014, 49, 1376-1381.	1.3	30
11	Peripheral Red Blood Cell Split Chimerism as a Consequence of Intramedullary Selective Apoptosis of Recipient Red Blood Cells in a Case of Sickle Cell Disease. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014066.	0.5	3
12	Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood, 2013, 122, 2751-2756.	0.6	44
13	Allogeneic cellular gene therapy in hemoglobinopathiesâ€”evaluation of hematopoietic SCT in sickle cell anemia. Bone Marrow Transplantation, 2012, 47, 227-230.	1.3	39
14	Higher CD3+ and CD34+ cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia. Bone Marrow Transplantation, 2012, 47, 107-114.	1.3	32
15	Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a011825-a011825.	2.9	123
16	T Cell-Depleted HlA-Haploidentical Stem Cell Transplantation in Thalassemia Young Patients. Mental Illness, 2011, 3, e13.	0.8	38
17	Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood, 2010, 115, 1296-1302.	0.6	98
18	Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood, 2010, 115, 4597-4604.	0.6	102

#	Article	IF	Citations
19	Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia. Annals of the New York Academy of Sciences, 2010, 1202, 149-154.	1.8	37
20	Late-Onset Hemorrhagic Cystitis in Children after Hematopoietic Stem Cell Transplantation for Thalassemia and Sickle Cell Anemia: A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir. Biology of Blood and Marrow Transplantation, 2010, 16, 662-671.	2.0	74
21	Immunohematologic Reconstitution in Pediatric Patients after T Cell-Depleted HLA-Haploidentical Stem Cell Transplantation for Thalassemia. Biology of Blood and Marrow Transplantation, 2010, 16, 1557-1566.	2.0	19
22	The impact of hematopoietic stem cell transplantation on the management of thalassemia. Expert Review of Hematology, 2009, 2, 335-344.	1.0	3
23	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA AND SICKLE CELL DISEASE. EXPERIENCE OF MEDITERRANEAN INSTITUTE OF HEMATOLOGY IN A MULTI-ETHNIC POPULATION.. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009027.	0.5	6
24	Functional interleukinâ€7/interleukinâ€7RÎ±, and SDFâ€1Î±/CXCR4 are expressed by human periodontal ligament derived mesenchymal stem cells. Journal of Cellular Physiology, 2008, 214, 706-713.	2.0	46
25	Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplantation, 2008, 42, 397-404.	1.3	42
26	Altered Clonogenic Capability and Stromal Cell Function Characterize Bone Marrow of HIVâ€Infected Subjects with Low CD4⁺T Cell Counts Despite Viral Suppression during HAART. Clinical Infectious Diseases, 2008, 46, 1902-1910.	2.9	64
27	T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. Aids, 2006, 20, 2033-2041.	1.0	95
28	Immunodysregulation of HIV disease at bone marrow level. Autoimmunity Reviews, 2005, 4, 486-490.	2.5	33
29	HIV Type 1 Protease Inhibitors Enhance Bone Marrow Progenitor Cell Activity in Normal Subjects and in HIV Type 1-Infected Patients. AIDS Research and Human Retroviruses, 2005, 21, 51-57.	0.5	13
30	Bone Marrow Clonogenic Capability, Cytokine Production, and Thymic Output in Patients with Common Variable Immunodeficiency. Journal of Immunology, 2005, 174, 5074-5081.	0.4	52
31	Idiopathic CD4+ Lymphocytopenia May Be due to Decreased Bone Marrow Clonogenic Capability. International Archives of Allergy and Immunology, 2005, 136, 379-384.	0.9	45
32	Decreased apoptosis of bone marrow progenitor cells in HIV-1-infected patients during highly active antiretroviral therapy. Aids, 2004, 18, 1335-1337.	1.0	14
33	Interleukin 7 production by bone marrow-derived stromal cells in HIV-1-infected patients during highly active antiretroviral therapy. Aids, 2002, 16, 2231-2232.	1.0	17
34	Improvement of interleukin 2 production, clonogenic capability and restoration of stromal cell function in human immunodeficiency virus-type-1 patients after highly active antiretroviral therapy. British Journal of Haematology, 2002, 118, 864-874.	1.2	21
35	Recovery of haematopoietic abnormalities in HIV-1 infected patients treated with HAART. Aids, 1999, 13, 2486.	1.0	10